David Parker

David, who has more than 20 years of private equity experience, joined Ampersand in 1994.
He served as full time CFO and head of Corporate Development at Ampersand portfolio companies NOVEX (1997) and Victory Pharma (2007-2010), in each case returning as a General Partner to Ampersand.
David is based in our Amsterdam office.
His current and past board seats include Avista Pharma, Bako, Bioventus, GenDx, Gyros PTI, MedPharm, NOVEX, Roadrunner Pharmacy, Signature Genomic Labs and Tjoapack.
Prior to joining Ampersand, David spent a combined five years in management consulting at Bain and Mercer and four years in corporate lending at Bank of Boston.
He holds a B.A.
in Government with a minor in Economics from Dartmouth and a M.B.A.
from Wharton.